PMV Pharmaceuticals, Inc. reported a corporate update and financial results for the first quarter of 2025, focusing on the ongoing Phase 2 PYNNACLE clinical trial evaluating rezatapopt, a treatment ...

GAAP EPS loss widened to $(0.41), reflecting higher R&D spending and no revenue. R&D expenses increased to $18.4 million (GAAP), compared to $14.6 million for Q2 2024, as PMV Pharmaceuticals advanced ...

PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals (PMVP), Inc. , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies ...

PRINCETON, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals (PMVP), Inc. , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies ...

CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...

DOYLESTOWN, Pa.--PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53 targeted small molecule drugs for the treatment of cancer, announced today the completion of a $30 million ...

PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...

PMV Pharmaceuticals, Inc. has announced that its CEO, David H. Mack, and Chief Development Officer, Deepika Jalota, will participate in upcoming investor conferences, specifically the TD Cowen Annual ...

Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors ...

DOYLESTOWN, Pa. & PRINCETON, N.J.--(BUSINESS WIRE)--PMV Pharmaceuticals, Inc., and Chiromics LLC today announced that they have entered into a collaboration whereby PMV Pharma has a non-exclusive ...